▶ SURVODUTIDE · SUBTOPIC · MECHANISM
SURVODUTIDE Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim as BI 456906. Combines incretin-driven glycemic control with glucagon-driven thermogenesis. Phase 3 SYNCHRONIZE program targets obesity and NASH simultaneously.
PHARMACOKINETIC HALF-LIFE
Reported half-life for SURVODUTIDE: ~7 days (once-weekly). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
SURVODUTIDE is a defined sequence: Modified glucagon backbone with dual receptor selectivity. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
SURVODUTIDE is tagged in 2 mechanism categories on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The incretin axis encompasses GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), gut hormones released in response to nutrient intake that account for roughly 70% of postprandial insulin secretion. Drugs targeting this axis include single GLP-1 agonists (GLP-3), dual GLP-1/GIP agonists (GLP-2), and triple GLP-1/GIP/glucagon agonists (GLP-1). The axis is the largest commercial pharma category of the 2020s and is responsible for the metabolic-medicine revolution underway in obesity, type 2 diabetes, and cardiometabolic disease.
Lipolysis is the breakdown of triglycerides in adipose tissue, driven by hormone-sensitive lipase activation downstream of cAMP elevation. GH-axis peptides (GH-axis reference) preferentially target visceral adipose. Glucagon-receptor agonism (the third arm of GLP-1) also drives hepatic lipid mobilization.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Le Roux 2024 Lancet Diabetes Endocrinol · placebo-subtracted weight loss 14.9% at 4.8 mg/wk in 46-week Phase 2.
Improvement in liver fat fraction + histology endpoints, supporting dedicated NASH Phase 3 program.
MECHANISM Q+A
▶ What is survodutide?
Survodutide (BI 456906) is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma for obesity and NASH/MASH research.
▶ Why combine glucagon agonism with GLP-1?
Glucagon receptor activation increases hepatic lipolysis and energy expenditure; GLP-1 reduces appetite. The combination targets both intake and expenditure, theoretically producing greater fat-mass reduction than GLP-1 monotherapy.
CITED LITERATURE
- Le Roux CW, et al.. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024. PMID 38219768. link
- Boehringer Ingelheim. A study of survodutide in adults with overweight or obesity (SYNCHRONIZE-1). ClinicalTrials.gov · Phase 3 2024. NCT06066515. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19